| RGNX Snapshot | |
|---|---|
| REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland. | |
| VALUATION DATA | |
| Market Capitalization | $790,078,000 | Price to Sales | 1.00 |
| Earnings per Share | $-6.0200 |
| PE Ratio | None |
| PRICE DATA | |
| Most Recent Close | $15.6900 |
| 52 Week High | $9.83 |
| 52 Week Low | $2.848 |
| 50-Day Moving Average | $7.78 |
| 200-Day Moving Average | $-2.93 |
| All data are from Alpha Vantage as of today. For more infomation on RGNX see Stock Dividend, Valuation, Price and Financial Data for Investors | |
Custom Search